After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…
Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis
A study identified denosumab as a useful treatment for patients initiating or continuing glucocorticoids who are at risk for fractures. Denosumab had clinical effects similar to risedronate but was more effective than risedronate in the improvement of bone mineral density at the lumbar spine…
Romosozumab Has Biggest BMD Benefit in First Year of Treatment
NEW YORK (Reuters Health)—Romosozumab shows smaller benefits for increasing bone mineral density (BMD) in the second year of treatment compared to the first, new research suggests. The extension of a phase 2 study in postmenopausal women with low bone mass also found BMD decreased sharply when patients on romosozumab were switched to placebo after two…
ACR Program Encourages Innovation & Opportunity
With a steadily diversifying U.S. population, the professional and societal consequences of health disparities continue to grow. Rheumatologists may need to innovate to prevent these disparities for their patients. A new ACR program will focus on member-led projects that reduce health racial and ethnic disparities for patients with rheumatic disease…
Cutaneous Lupus Tied to Risk for Coexisting Autoimmune Conditions
NEW YORK (Reuters Health)—Patients with cutaneous lupus erythematosus (CLE) should be monitored closely for other autoimmune conditions, researchers suggest. Dr. Benjamin Chong, Dr. Linda Hynan and Elaine Kunzler of the University of Texas Southwestern Medical Center in Dallas analyzed data from 129 adults in the UTSW Cutaneous Lupus Registry (mean age, 49; 79% women). Individuals…
Existing CT Scans as Good as DXA for Assessing Hip Fracture Risk
NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…
FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine
The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…
The Social Workers’ Role in Rheumatology Care & Patient Advocacy
Patients with rheumatic disease require a team of specialists working together to meet the patient’s needs. Social workers can advocate for these patients and play a variety of other roles to help them manage their disease…
Gut Microbiota Directly Affects Inflammatory Arthritis
Gut microbiota may provide insight into important environmental triggers for autoimmune diseases. New research in mice indicates that intestinal dysbiosis triggers a mucosal immune response that stimulates T and B cells, which are critical to the development of inflammatory arthritis…
Diclofenac May Boost MI Risk in Patients with Spondyloarthritis
NEW YORK (Reuters Health)—Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, but not in those who take naproxen, researchers say. Maureen Dubreuil, MD, MSc, of Boston University School of Medicine, and colleagues analyzed 20 years of medical records from the U.K.’s Health Improvement…
- « Previous Page
- 1
- …
- 345
- 346
- 347
- 348
- 349
- …
- 820
- Next Page »